Analyst Conference Summaries

Biotechnology Investor Aids

Regeneron Pharmaceuticals
REGN

conference date: November 6, 2018 @ 5:30 AM Pacific

Regeneron: A Buy On Dupixent And Pipeline [August 15, 2018 at Seeking Alpha]

Regeneron Unknown: Eylea Future Competition Effects [May 17, 2018]

Analyst Conference Notes by William P. Meyers
2018
 
May 3, 2018
August 8, 2018
Nov. 6, 2018
 
2017
May 4, 2017
August 3, 2017
Nov. 8, 2017
Feb. 8, 2018
2016
05/05/2016
08/04/2016
11/04/2016
02/09/2017
2015
05/07/2015
08/04/2015
11/04/2015
02/09/2016
2014
05/08/2014
08/05/2014
11/04/2014
02/10/2015
2013
not available

08/06/2013
11/05/2013
 02/11/2014

Regeneron (REGN) is a biotechnology company currently providing Eylea for Wet Macular Degeneration, Arcalyst for Cryopyrin-Associated Periodic Syndromes (CAPS), and Zaltrap for metastatic colorectal cancer.

Regeneron web site
Regeneron investor relations page

Note that I owned Regeneron stock from June 24, 2014 to January 10, 2017


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 ISRG
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2017 William P. Meyers